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Anti-tumor necrosis factor alpha (TNF-α) antibodies have an excellent effect in patients with 
inflammatory bowel disease (IBD). However, the effect is not optimal because a sufficient 
concentration of antibodies cannot be maintained at the site of inflammation. Thus, a 
macromolecular complex was developed with schizophyllan (SPG) and antisense oligonucleotide. In 
the present study, SPG-antisense TNF-α complex was prepared, and its therapeutic efficacy was 
examined using a dextran sodium sulfate (DSS)-induced colitis model. TNF-α production in CD11b+ 
macrophages was significantly increased in the colon of DSS-treated mice. Dectin-1, which is a 
receptor of SPG, binds with SPG and is subsequently taken into the cells via phagocytosis. The 
expression of dectin-1 by CD11b+ macrophages was significantly increased in DSS-treated mice. 
Flow cytometry revealed that the uptake of SPG-antisense TNF-α in the macrophages was efficient. 
TNF-α production was significantly suppressed by SPG-antisense TNF-α in vitro, which was 
administered via enema to evaluate its efficacy. The intrarectal administration of SPG-antisense 
TNF-α ameliorated intestinal inflammation. In this study, we showed the delivery system that 
conjugates SPG and antisense can have a higher therapeutic efficacy. Thus, the new therapeutic 
approach presented in this study may be used in the management of IBD. 
 













Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal 
tract. The two major IBD phenotypes are ulcerative colitis (UC) and Crohn’s disease (CD) [1]. The 
pathogenesis of IBD is complex; however, the dysregulation of the intestinal immune system plays a 
key role in the development of the condition [2]. In a previous study, an increased level of TNF-α 
was detected in the mucosa of patients with IBD, and the intestinal inflammatory process shifted to 
Th1 during cytokine production [3, 4]. In animal models, anti-TNF-α antibodies (Abs) improved 
intestinal inflammation, indicating that they were effective in increasing cytokine production by Th1 
cells in chronic inflammatory disease [5]. Thus, TNF-α has a pathogenic role as anti-TNF-α Abs 
significantly improve intestinal inflammation in IBD [6]. Ant-TNF-α Abs were then widely used in 
patients with IBD.  
Although anti-TNF-α Abs were found to be significantly effective in the treatment of IBD [7], 
high doses are required to improve intestinal inflammation. Therefore, the incidence of adverse 
events, such as tuberculosis, lymphoma, and development of antibodies against anti-TNF-α Abs, is 
increasing [8]. Thus, the strategies used in biological treatment must be improved to downregulate 
TNF-α in IBD. Recently, several studies have shown that small interfering RNA (siRNA) and 
antisense oligonucleotides (ASOs) inhibiting the production of TNF-α are useful for the treatment of 
IBD [9-11]. However, previous studies have investigated the effect of siRNA and ASOs 
administered orally and subcutaneously, and only few reports have provided local treatment via 
enema. 
Schizophyllan (SPG), which belongs to the β-(1–3) glucan family (Figure 1A), forms a triple 
helix in neutral solution. This triple helix changes to three single chains in alkaline solution (Figure 
1B). The single chain of SPG, which is present in alkaline solutions, reverts to triple helix via 
hydrophobic and hydrogen bonding interactions in neutral solutions. During this process, we found 





(Figures 1B, C) [12]. By contrast, a short antisense oligonucleotide does not form a complex with 
SPG. In this study, an SPG-based drug delivery system (DDS) with oligonucleotides comprising 
ASOs and poly(dA) was developed to deliver ASOs to target sites. SPG has several advantages. That 
is, the one used in this study was medical grade [13] and was up taken in macrophages and dendritic 
cells (DCs) via phagocytosis [14]. Furthermore, previous studies showed that Dectin-1, which was 
known to be the receptor of SPG, had a key role in the phagocytosis of SPG in macrophages [15, 16]. 
In our study, the topical administration of SPG-antisense TNF-α suppressed TNF-α 




2.1. Cytokine production in the mucosa of DSS-treated mice 
The expressions of TNF-α and other proinflammatory cytokines, such as interleukin (IL)-1 
and IL-6, in the mucosa of DSS-treated mice were examined via real-time polymerase chain reaction 
(PCR). The expression of these proinflammatory cytokines in the DSS-treated mice was significantly 
increased (Figure 2A). Since the expression of TNF-α in the mucosa of DSS-treated mice was 
increased, we examined the production of TNF-α in CD11b+ cells isolated from lamina propria (LP) 
cells. The production of TNF-α in CD11b+ cells cultured with 10 ng/mL of LPS was significantly 
higher in DSS-treated mice than in DSS-untreated mice (Figure 2B). Since CD11b+ cells highly 
produced TNF-α in the mucosa of DSS-treated mice, we targeted TNF-α in CD11b+ cells to improve 
colitis. 
 
2.2. The expression of dectin-1 in CD11b+ cells was significantly increased in the mucosa of 
DSS-treated mice 





binds with -glucans, including SPG [17]. The expressions of dectin-1 in DSS-untreated and 
DSS-treated mice were examined. Results showed that the expression in the mucosa was 
significantly higher in DSS-treated mice than in DSS-untreated mice (Figure 3A). Subsequently, we 
examined the expression of dectin-1 in CD11b+ cells of LP. FACS analysis showed that the 
expression of dectin-1 in CD11b+ cells increased in the LP of DSS-treated mice compared with 
DSS-untreated mice (Figure 3B). In this study, since most CD11b+ cells expressed dectin-1, the 
SPG-based delivery system was assumed to be taken up into  CD11b+ cells via dectin-1. 
 
2.3. SPG-antisense TNF-α inhibited the production of TNF-α in CD11b+ cells 
We examined the uptake rate of SPG-antisense TNF-α at different time points (Figure 4A). 
The CD11b+ cells in the LP were cultured with SPG-antisense TNF-α at 0, 1, 2, and 4 h. FACS 
analysis revealed that approximately 40% was taken up into the macrophages for 4 h after the 
administration of the complex. Furthermore, we performed immunofluorescence to examine whether 
the SPG-antisense TNF-α was taken up into CD11b+ cells in vitro (Figure 4B). Antisense TNF-α and 
SPG were labeled with Alexa546 and FITC, respectively. As shown in Figure 4B, a large number of 
Alexa546 and FITC double positive CD11b+cells was detected in the SPG-antisense TNF-α group. 
This result showed that the SPG-antisense TNF-α was highly taken up in CD11b+ cells compared 
with antisense TNF-α without DDS. Furthermore, we investigated whether SPG-antisense TNF-α 
inhibits the production of TNF-α in CD11b+ cells. The CD11b+ cells at increasing concentrations of 
SPG-antisense TNF-α were cultured with 10 ng/mL of LPS in vitro, and TNF-α production was 
measured. SPG-antisense TNF-α significantly inhibited the production of TNF-α based on the 
concentration of SPG-antisense TNF-α (Figure 5A). Antisense TNF-α and SPG did not inhibit the 
production of TNF-α (Figure 5B). Furthermore, we investigated whether SPG and SPG-antisense 
TNF-α stimulated CD11b+ cells via dectin-1 and induced TNF-α production. Results showed that 






2.4. Administration of SPG-antisense TNF-α improved colitis in DSS-treated mice 
Results showed that SPG-antisense TNF-α inhibited the production of TNF-α in vitro. To 
investigate the therapeutic effect of SPG-antisense TNF-α in vivo, 0.2mg/kg SPG-antisense TNF-α 
was administered via enema twice per week in DSS-treated mice (Figure 6A),since 0.2 mg/kg of 
SPG-antisense TNF-α was equivalent to 50 nM. The therapeutic effect of SPG-antisense TNF-α was 
evaluated on day 14 to evaluate for disease severity and cytokine production. The topical 
administration of SPG-antisense TNF-α significantly inhibited weight loss and colon shortening 
(Figures 6A, B). On endoscopy, edema and erosion in the intestine improved after treatment with 
SPG-antisense TNF-α (Figure 6C). Histological examination also revealed a significant improvement 
in mucosal damage and inflammation after treatment with SPG-antisense TNF-α (Figures 7A, B). 
The production of TNF-α and other proinflammatory cytokines in the colon was inhibited by 
SPG-antisense TNF-α (Figure 7C), and this result indicated that the topical administration of 
SPG-antisense TNF-α was effective in inhibiting the production of TNF-α in CD11b+ cells and 
improved intestinal inflammation.  
 
3. Discussion 
TNF-α is produced by macrophages and T cells and is a key cytokine in the development of 
inflammation. Moreover, it plays a role in the pathogenesis of IBD since the level of TNF-α 
increases in the serum of patients with UC and CD [18]. Furthermore, patients with IBD have 
increased levels of TNF-α in the inflamed mucosa [3, 19] and TNF-α produced by CD14+ 
macrophages [20]. Although the rate of clinical response to anti-TNF-α Abs is approximately 60%, 
lack of response and disease relapse are commonly observed during maintenance therapy [21-23]. 





several reasons [24], which is mainly attributed to the development of neutralizing Abs against 
therapeutic protein [25, 26]. The complex produced in this study is nano-sized, and it has a minimal 
effect when acts locally. Therefore, it does not require a large amount of protein similar to antibody 
therapy. However, the production of an antibody is considered challenging. 
Macrophages and DCs recognize pathogens, such as fungi and mycobacteria, using PRRs, 
activate innate immunity, and eliminate pathogens. Dectin-1 is a type II C-type lectin receptors that 
belong to the PRRs, and it is highly expressed in macrophages and DCs and binds with the 
carbohydrate structures of pathogens [27, 28]. Previous studies have shown that dectin-1 is the 
receptor for β-1, 3-linked glucans and that it is a protective host against fungi [29, 30]. The level of 
dectin-1 increases in the inflamed mucosa but not in a disease-specific manner [31]. In fact, the 
expression of dectin-1 in intestinal macrophages increased in the inflamed mucosa in DSS colitis. 
Therefore, ASO with SPG is efficiently taken up by dectin-1-positive macrophages and DCs at the 
site of inflammation. The dectin-1 signaling pathway directly activates nuclear factor kappa and 
induces proinflammatory cytokines, such as TNF-α and IL-6 [32]. However, the mechanism 
underlying the effect of dectin-1 in IBD remains unclear. Heinsbroek et al. have shown that the lack 
of dectin-1 did not improve intestinal inflammation in the colitis mouse model, although some 
differences were observed in the innate immune response to gut flora between dectin-1-deficient 
mice and normal mice [33]. In our study, SPG alone and SPG-antisense TNF-α did not induce the 
production of TNF-α in CD11b+ macrophages. In addition, they did not exacerbate DSS-induced 
colitis. Our study showed that the SPG-based DDS did not induce the production of proinflammatory 
cytokines and did not cause intestinal inflammation via Dectin-1 both in vivo and in vitro.  
ASOs have been used in patients with IBD to inhibit specific targets, including Smad7, 
intercellular adhesion molecule (ICAM)-1, and toll-like receptor (TLR) 9. Mongersen, which is a 





a phase II clinical trial of patients with CD, Mongersen significantly improved Crohn’s Disease 
Activity Index scores [34]. Although therapeutic effects are expected, a phase III clinical trial did not 
show that such treatment was significantly effective. The expression of ICAM-1, which is an 
adhesion molecule mediating the adhesion and migration of leucocytes from the blood to the 
intestine, increased in the endothelial cells in IBD [35, 36]. Alicaforsen is a 20-base 
phosphorothioate ASO that hybridizes the mRNA of ICAM-1 [37]. Although Alicaforsen did not 
have a therapeutic effect in patients with CD, it was found to be effective in patients with UC when 
administered via enema according to several studies [38]. The expression of TLR9, which increases 
in the inflamed intestine, has been considered an important pathogen in UC [39]. Cobitolimod is an 
ASO that is recognized by TLR9. Currently, in a phase II clinical study of cobitolimod in patients 
with moderate to severe UC, enema was performed. Treatment with ASO has been used clinically; 
however, its efficacy was not confirmed in multicenter clinical trials. 
Based on these results, the use of ASO and siRNA has several disadvantages. Hydrolysis 
mediated by deoxyribonuclease causes the instability of ASO and siRNA. Thus, additional strategies 
are required for them to reach the intestine and stay in the intestinal mucosa, even though 
inflammation causes a loss of mucous gel layers and the disruption of epithelial cell barrier in the 
intestine. The administration of ASOs with SPG directly to an inflammatory site forming an ulcer 
effectively acts on the inflammatory site and does not affect the whole body. The SPG-based 
antisense delivery system has several advantages. That is, the SPG complex was stable in vivo and 
did not dissolve in the presence of deoxyribonuclease, and it was effectively taken up by 
macrophages via dectin-1 and phagocytosis. Therefore, the topical administration of the 
SPG-antisense TNF-α significantly inhibited the production of TNF-α by the macrophages and 
improved intestinal inflammation. These complexes are considered effective against human IBD 
when administered orally in the form of PH-dependent capsules or via enema. Thus, the efficacy and 






4. Materials & Methods 
4.1. Preparation of SPG-antisense TNF-α 
SPG (Mw = 1.5 × 10
5, via gel-permeation chromatography) was provided by Mitsui Sugar Co., Ltd. 
(Tokyo, Japan). ASO for TNF-α (AACCCATCGGCTGGCACCAC-(dA)60) was synthesized at 
FASMAC Co., Ltd. (Kanagawa, Japan) and was purified using high-performance liquid 
chromatography. SPG can dissociate from a triple helix to a single chain in 0.25 N NaOH for 3–5 
days. The single chains of SPG were mixed with antisense TNF-α in phosphate buffer solution (pH 
7.4) and were stored overnight at 4 °C. The final DNA concentrations of the complex were measured 
using ultraviolet absorbance. The formation of SPG-based antisense complex was confirmed via 
polyacrylamide gel electrophoresis.  
 
4.2. Mice 
C57BL/6 mice were purchased from SLC (Fukuoka, Japan) and Kyudo Laboratory (Saga, 
Japan). All experiments were performed under specific pathogen-free conditions at Kurume 
University and Fukuoka University. The mice were used according to the approved protocols of the 
Animal Care and Use Committees of Kurume University Animal and Fukuoka University. 
 
4.3. DSS-induced colitis model 
Colitis was induced with 3% (w/v) DSS (40,000–50,000 MW) (MP Biomedicals, Irvine, CA) 
drinking water. Eight-week-old female mice were provided with 3% DSS water for 5 days. The body 
weights of the mice were assessed to evaluate the development of colitis. Then, they were sacrificed 
on day 14. The colon was removed and used in some experiments. A part of the colon was fixed in 
4% formaldehyde and was stained with hematoxylin and eosin. Histology was scored, as described 





severe; extent (E) as 0 = none, 1 = mucosa, 2 = mucosa and submucosa, and 3 = transmural; 
regeneration (R) as 0 = complete regeneration, 1 = almost complete regeneration, 2 = regeneration 
with crypt depletion, 3 = surface epithelium not intact, and 4 = no tissue repair; crypt damage (C) as 
0 = none, 1 = 1/3 of basal damage, 2 = 2/3 of basal damage, 3 = only the surface epithelium is intact, 
and 4 = loss of the entire crypt and epithelium; and percent involvement (P) as 1 = 1%–25%, 2 = 
26%–50%, 3 = 51%–75%, and 4 = 76%–100%. The severity of colitis was evaluated using the total 
histological scores of I+E+R+C+P. 
 
4.4. Cell culture and cytokine assay 
For cell culture, mononuclear cells were isolated from the LP in the colon. Briefly, the 
intestinal epithelial cells were removed from the colon with 1 mmol/L of EDTA. Then, colonic 
tissues were shredded and digested by 100 U/mL of collagenase type 2. The LP cells were passed 
through a 100-m nylon membrane and were purified using a 45%/72% Percoll gradient (GE 
Healthcare, Piscataway, NJ). The CD11b+ cells were isolated via magnetic activated cell sorting 
using anti-CD11b MicroBeads (Miltenyi Biotec, Auburn, CA). Moreover, 1 x 106 CD11b+ cells 
were cultured in 96-well plates with 10 ng/mL of LPS (Sigma-Aldrich, St. Louis, MO). The 
production of TNF-α in culture supernatants were measured using an enzyme-linked immunosorbent 
assay kit (Catalog # BMS607HS) for TNF-α (Invitrogen, Waltham, MA)). The absorbance was 
measured using an ELISA reader at a wavelength of 450 nm. The relative TNF-α productions with 
several concentrations of SPG, antisense TNF-α, and SPG-antisense TNF-α, normalized to TNF-α 
production without them, were measured as inhibition rate. 
 
4.5. Real-time PCR 
RNA was extracted from the colon and CD11b+ cells using Trizol (Invitrogen, Carlsbad, CA). RNA 





Japan). cDNA was quantified using real-time PCR (RT-PCR) with an ABI PRISM 7000 (Applied 
Biosystems Inc., Foster City, CA). RT-PCR for TNF-α, IL-1, IL-6, dectin-1, and GAPDH was 
performed using the TaqMan probe. For the relative quantification of gene expression, the 
comparative Ct method was used. The final amount of the target gene, normalized to an endogenous 
reference gene as GAPDH (ΔCt=Ct target gene – Ct reference gene) was determined using the 
formula 2−ΔCt. 
 
4.6. Flow cytometric analysis and immunofluorescence 
LPMCs were prepared in phosphate-buffered saline buffer with 1% bovine serum albumin 
and 0.5% sodium azide and were incubated with FITC labeled rat anti-mouse CD11b mAb (clone 
M1/70) and PE-labeled rat anti-mouse dectin-1 mAb (clone 2A11). The expression of CD11b and 
dectin-1 was examined via flow cytometry analysis (FACSVerse, BD Biosecience). CD11b+ cells 
isolated from LPMCs were incubated with Alexa546-labeled SPG-antisense TNF-α at different time 
points (0, 1, 2, and 4 h). The uptake of the complex was determined via flow cytometry. For 
immunofluorescence, CD11b+ cells were incubated with Alexa546-labeled antisense TNF-α or FITC 
labeled-SPG-Alexa546-antisense TNF-α for 4 h. Fluorescence microscope analyses were performed 
to detect antisense TNF-α or SPG-antisense TNF-α in CD11b+ cells using a BZ-9000 digital 
fluorescence microscope (Keyence, Osaka, Japan).  
 
4.7. Treatment using SPG-antisense TNF-α 
For therapeutic experiments in DSS-treated mice, 0.2 mg/kg of SPG, antisense TNF-α, or 
SPG-antisense TNF-α was administered to the colon via enema twice a week (days 0, 3, 7, and 10). 
To evaluate the activity of colitis, a video endoscopic system for mice was used (Karl Storz, 
Tuttlingen, Germany) [41]. The endoscopic findings in DSS-treated mice include the disappearance 





blinded to the study evaluated the presence of colitis on day 14. 
  
4.8. Statistical Analysis 
Student t-test or the Mann–Whitney U test was used for the analysis of quantitative variables 
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Figure 1. Schematic illustration showing a complex structure composed of antisense 
oligonucleotides (ASOs) with a dA tail and schizophyllan (SPG). (A) Chemical structure of SPG. 
(B) Schematic illustration of the SPG–ASO complex. (C) A triple-stranded complex was formed 
from one DNA and two SPG strands. 
 
Figure 2. Tumor necrosis factor alpha (TNF-α) is up-regulated in DSS-induced colitis. (A) 
Interleukin (IL)-1, IL-6, and TNF-α mRNA expressions in colon specimens were assessed using 





glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. (B) CD11b+ cells, isolated from the 
lamina propria in the dextran sodium sulfate-treated mice and untreated mice, were cultured with 10 
ng/mL of LPS. The production of TNF-α was measured using an enzyme-linked immunosorbent 
assay. Data were presented as the mean of the three independent experiments. 
 
Figure 3. The expression of dectin-1 in the receptor of schizophyllan increased in dextran 
sodium sulfate-induced acute colitis. 
(A) Dectin-1 mRNA expression in the colon was evaluated using real-time polymerase chain 
reaction. Data were normalized to the expression of GAPDH mRNA. (B) Dectin-1 and CD11b 
expressions in the lamina propria were analyzed via FACS analysis. Data were presented as the mean 
of the three independent experiments. 
 
Figure 4. Schizophyllan (SPG)-antisense tumor necrosis factor alpha (TNF)-α inhibited the 
production of TNF-α induced by LPS in vitro. (A) FACS analysis revealed that SPG-antisense 
TNF-α labeling with Alexa 546 was taken up into CD11b+ cells in a time-dependent manner. (B) 
Immunofluorescence in CD11b+ cells was performed using labeling antisense TNF-α with Alexa 
546 and the SPG with FITC. CD11b+ cells effectively taken up the SPG-antisense TNF-α compared 
with antisense TNF-α alone.  
 
Figure 5. Schizophyllan (SPG)-antisense tumor necrosis factor alpha (TNF-α) inhibits the 
production of TNF-α in CD11b cells. 
(A) CD11b+ cells in the lamina propria were cultured with several concentrations of SPG-antisense 
TNF-α (complex), antisense TNF-α, and SPG as a control. After 10 h, 10 ng/mL of LPS was added 
under each condition, and the cells were cultured for 24 h. The production of TNF-α was measured 





standard deviation. (B) CD11b+ cells were cultured with SPG, antisense TNF-α, SPG-antisense 
TNF-α, and LPS for 24 h. The production of TNF-α was measured using an enzyme-linked 
immunosorbent assay (n = 5 per group). 
 
Figure 6. Attenuation of dextran sodium sulfate (DSS)-induced colitis via the administration of 
schizophyllan (SPG)-antisense tumor necrosis factor alpha (TNF-α). A total of 0.2 mg/kg of 
SPG-antisense TNF-α (complex), antisense TNF-α (antisense), SPG, and phosphate buffer solution 
used as a control were administered via enema twice weekly in mice receiving DSS (n = 8 per group). 
(A) Body weights are presented as percentage of the initial weight on day 0. (B) The length of the 
colon from the terminal ileum to the rectum. (C) Endoscopic findings of the colon. 
 
Figure 7. Administration of schizophyllan (SPG)-antisense tumor necrosis factor alpha 
(TNF-α) inhibited cytokines in dextran sodium sulfate (DSS)-induced colitis. (A) Hematoxylin 
and eosin staining of the colon (original magnification: × 100). (B) The histological scores were 
evaluated. (C) TNF-α, Interleukin (IL)-1, and IL-6 mRNA expressions in the colon were assessed 
using real-time polymerase chain reaction (n = 5 per group). Data were normalized to the expression 
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